Related Experiment Video
Updated: Jun 17, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
A meta-analysis of the bradykinin B2 receptor gene --58C/T polymorphism with hypertension
Wenquan Niu1, Yue Qi, Pingjin Gao
1State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China. niuwenquan@yahoo.cn
Background And Objective:
Numerous studies have attempted to associate -58C/T polymorphism of bradykinin B2 receptor gene (BDKRB2) with hypertension, whereas results were often irreproducible. We performed a meta-analysis aiming to provide a comprehensive evaluation of this polymorphism and hypertension.
Methods:
Case-control reports published in English were searched totaling four studies with six populations (823 cases and 916 controls). Random-effects model was applied irrespective of between-study heterogeneity, and study quality was assessed in duplicate.
Results:
Compared with -58C allele carriers, those with -58T allele had a lower yet nonsignificant risk for hypertension (OR=0.86; 95% CI: 0.68-1.09; P=0.21). Lack of significance persisted after combining those with genotypes -58TC and -58TT together (OR=0.87; 95% CI: 0.67-1.09; P=0.21) or with -58TC and -58CC together (OR=0.75; 95% CI: 0.48-1.18; P=0.22) in association with hypertension. Sensitivity analyses by race indicated that comparison of -58T versus -58C generated a protective effect for hypertension in Asians (OR=0.77; 95% CI: 0.58-1.02; P=0.07) and African-Americans (OR=0.65; 95% CI: 0.43-0.98; P=0.04), but a risk effect in Caucasians (OR=1.22; 95% CI: 0.92-1.61; P=0.17). No publication bias was observed.
Conclusions:
Our results suggested that -58T allele exhibited a protective effect on hypertension in Asians and African-Americans, yet a risk effect in Caucasians.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Antihypertensive Drugs: Action of β1 Blockers
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hypertension II: Pathophysiology